GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » YoY EPS Growth

Immuron (FRA:ANW) YoY EPS Growth : 0.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Immuron's YoY EPS Growth for the quarter that ended in Dec. 2023 was 0.00%.

Immuron's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.01.

Immuron YoY EPS Growth Historical Data

The historical data trend for Immuron's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron YoY EPS Growth Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only -33.33 50.00 -140.00 66.67 -25.00

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.75 62.50 -20.00 -66.67 -

Immuron YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Immuron's YoY EPS Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EPS Growth (A: Jun. 2023 )
=(Earnings per Share (Diluted) (A: Jun. 2023 )-Earnings per Share (Diluted) (A: Jun. 2022 ))/ | Earnings per Share (Diluted) (A: Jun. 2022 ) |
=(-0.01--0.008)/ | -0.008 |
=-25.00 %

Immuron's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.006--0.006)/ | -0.006 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Immuron's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANW) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » YoY EPS Growth
Comparable Companies
ASX:NOX ASX:ACR ASX:CHM ASX:1AI ASX:ATX ASX:ATH ASX:PAB ASX:RAD ASX:BTC ASX:1AD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IMRN:USA ANWA:Germany IMC:Australia
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Website
https://www.immuron.com.au
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines